
    
      This trial is a two-arm, multicenter, open labelled, prospective, randomized phase III
      studies. Eligible patients with locally advnaced colorectal cancer receiving oxlipaltin-based
      (less than 3 months) noeadjuvant treatment, the postoperative stage was high-risk stage II
      (ypT4N0M0) or stage III (ypTanyN1-2M0). These high risk patients will be randomly assigned,
      in a 1:1 ratio, to receive either mFOLFOXIRI or FOLFOX for 3 months as adjuvant chemotherapy.
    
  